Literature DB >> 27212699

Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization.

Maria Soares1, Sara Madeira1, Jorge Correia1, Maria Peleteiro1, Fátima Cardoso2, Fernando Ferreira3.   

Abstract

Molecular classification of feline mammary carcinomas (FMC) from which specific behavioral patterns may be estimated has potential applications in veterinary clinical practice and in comparative oncology. In this perspective, the main goal of this study was to characterize both the clinical and the pathological features of the different molecular phenotypes found in a population of FMC (n = 102), using the broadly accepted IHC-based classification established by St. Gallen International Expert Consensus panel. The luminal B/HER2-negative subtype was the most common (29.4%, 30/102) followed by luminal B/HER2-positive subtype (19.6%, 20/102), triple negative basal-like (16.7%, 17/102), luminal A (14.7%, 15/102), triple negative normal-like (12.7%, 13/102) and finally, HER2-positive subtype (6.9%, 7/102). Luminal A subtype was significantly associated with smaller tumors (p = 0.024) and with well differentiated ones (p < 0.001), contrasting with the triple negative basal-like subtype, that was associated with larger and poorly differentiated tumors (p < 0.001), and with the presence of necrotic areas in the tumoral lesion (p = 0.003). In the survival analysis, cats with Luminal A subtype presented the highest survival time (mean OS = 943.6 days) and animals with triple negative basal-like subtype exhibited the lowest survival time (OS mean = 368.9 days). Moreover, two thirds (64%, 32/50) of the queens with multiple primary tumors showed different molecular subtypes in each carcinoma, revealing that all independent lesions should be analyzed in order to improve the clinical management of animals. Finally, the similarities between the subtypes of feline mammary tumors and human breast cancer, reveal that feline can be a valuable model for comparative studies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer model; Feline mammary carcinoma; Immunohistochemistry; Luminal B; Molecular subtype; Triple negative

Mesh:

Substances:

Year:  2016        PMID: 27212699     DOI: 10.1016/j.breast.2016.02.016

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  17 in total

Review 1.  Dissecting evolution and disease using comparative vertebrate genomics.

Authors:  Jennifer R S Meadows; Kerstin Lindblad-Toh
Journal:  Nat Rev Genet       Date:  2017-07-24       Impact factor: 53.242

Review 2.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

3.  HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

Authors:  Andreia Gameiro; Catarina Nascimento; Jorge Correia; Fernando Ferreira
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

4.  Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.

Authors:  Cláudia S Marques; Maria Soares; Ana Santos; Jorge Correia; Fernando Ferreira
Journal:  Oncotarget       Date:  2017-11-11

5.  Gene expression association study in feline mammary carcinomas.

Authors:  Daniela Ferreira; Bárbara Martins; Maria Soares; Jorge Correia; Filomena Adega; Fernando Ferreira; Raquel Chaves
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

6.  Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines.

Authors:  Fernando Ferreira; Raquel Chaves; Daniela Ferreira; Maria Soares; Jorge Correia; Filomena Adega
Journal:  Aging (Albany NY)       Date:  2019-07-12       Impact factor: 5.682

7.  Anaplastic Mammary Carcinoma in Cat.

Authors:  Maria Soares; Jorge Correia; Catarina Nascimento; Fernando Ferreira
Journal:  Vet Sci       Date:  2021-05-04

8.  HER2-positive feline mammary carcinoma.

Authors:  Cláudia Marques; Jorge Correia; Fernando Ferreira
Journal:  Aging (Albany NY)       Date:  2016-08       Impact factor: 5.682

9.  CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.

Authors:  Cláudia S Marques; Ana Rita Santos; Andreia Gameiro; Jorge Correia; Fernando Ferreira
Journal:  BMC Cancer       Date:  2018-07-16       Impact factor: 4.430

10.  Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Authors:  Hugo Murua Escobar; Ingo Nolte; José Luis Granados-Soler; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Ekkehard Schütz; Daniela Betz; Johannes Junginger; Marion Hewicker-Trautwein
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.